PTO/S8/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031* nt and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons	are required to respond to a coolection	OF PROPERTY OF MARKS & CONTROL & VALUE CAME CONTROL FILE
Substitute for form 1449A/PTO		Complete if Known
	Application Number	10/622,833
NFORMATION DISCLOSURE	Filing Date	July 21, 2003
TATEMENT BY APPLICANT	First Named Inventor	Richard A. SCHUMACHER et a
5)	Group Art Unit	Unassigned 1626
(use as many sheets as necessary)	Examiner Name	Unassigned
	Annual Control Manhael	MEMORY.28

			U.S. P	ATENT DOCUMENTS	
Examiner Initials	Cite No.1	U.S. Patent Docum	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-OD-YYYY
1000	1	5,591,776	T		1/7/1997
RI	2	5,889,014			3/30/1999
126	3	6,153,630			11/28/2000
Z	4	2002151566	1		. 10/17/2002
			T .		
					-
				:	
				· .	
		<u> </u>	1		
			T		

					FOREIG	N PATENT DOCUMENTS			
Exam		Cite No.	Office ³	Foreign Patent Docum	Kind Code ⁶	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Pessages or Relevant Figures Appear	۳
				WO 96-21435			7/18/1990		1, 2,
1	A			WO 02 074726			9/26/2002		.4
0	7								×
									
								·	

Date Considered red, whether or not citation is in con form with next communication to ap MPEP 609. Draw line through citation if not in confo

Unique clasion designation number. ² See attached Kinds of U.S. Palent Documents. ² Enter Office that Issued the document, by the two-letter code (WFPO Standard ST.3.) ² For Japanese patient documents, be indication of the year of the regin of the Emperor must precise the serial number of 15 majert document. ² Infect of document under the appropriate professions are indicated in the document under WFPO Gardard ST. 4 if possible. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: Tiss form is estimated to take 2.0 scors as complete. Time will very depressing upon the needs of the indicated case. Any of the complete terms belowed to the complete terms below does not be the control force, U.S. Patient and Trademark control, we shopped to 2021, but not not to the control force, U.S. Patient and Trademark Control, Weshopped, DC 2021, but Not St800 FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patients, P.O. Gorido, Necessity 1450.

* already considered on 9/2/05 tos Plo

Approved for use through 10/31/20/20. ONB 05:1-031=

U.S. Patent and Tracelement Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Radiution Act of 1995, no persons are required to respond to a collection of information unless to crossine a visit OMB covered number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/622,833 Filing Date July 21, 2003 First Named Inventor Richard A. SCHUMACHER et al Group Art Unit Unassigned 1626 Examiner Name Unassigned MEMORY-28 Attorney Docket Number

(use as many sheets as necessary) of

L ≈/			U.S. PATENT DOCUM	LENIS	
55m	ine Cite	U.S. Patent Document	Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where

1.55	Cite		Name of Fatchice of	Date of Publication of	rages, Columns, Lines, where
Initials	No.1	Number Kind Co		Cited Document	Relevant Passages or Relevant
-		(if know)		MM-DD-YYYY	Figures Appear
Rt		5,622,977	Warrellow et al.	04/22/1997	
14		5,633,257	Warrellow et al.	05/27/1997	
RA		5,679,696	Fenton et al.	10/21/1997	
RI		5,693,659	Head et al.	12/02/1997	
26		5,698,711	Palfreyman	12/16/1997	
1.6		5,710,160	Guay et al.	01/20/1998	
146		5,710,170	Guay et al.	01/20/1998	
Ret		5,712,298	Amschler	01/27/1998	
26		5,723,460	Warrellow et al.	03/03/1998	
igs		5,728,712	Montana et al.	03/17/1998	
2L		5,739,144	Warrellow et al.	04/14/1998	
Ro		5,776,958	Warrellow et al.	07/07/1998	
P		5,780,477	Head et al.	07/14/1998	
16		5,780,478	Alexander et al.	07/14/1998	
14		5,786,354	Warrellow et al.	07/28/1998	
/UE		5,798,373	Warrellow et al.	08/25/1998	
Pop		5,840,724	Fenton et al.	11/24/1998	
100		5,849,770	Head et al	12/15/1998	
Rh		5,859,034	Warrellow et al.	01/12/1999	
24		5,891,896	Warrellow et al.	04/06/1999	
120		5,866,593	Warrellow et al.	02/02/1999	
R		5,919,937	Lynch et al.	07/06/1999	
Rb		5,935,978	Fenton et al.	08/10/1999	
126		5,962,483	Warrellow et al.	10/05/1999	
M		5,962,492	Warrellow et al.	10/05/1999	
150		6,077,854	Warrellow et al.	06/20/2000	
PO		5,814,651	Duplantier et al	09/29/1998	
R-K		6,255,326	Ashton et al.	07/03/2001	
26		6,096,768	Ashton et al.	08/01/2000	
RA		6,162,830	Connor et al.	12/19/2000	
100		6,180,650	Frenette et al.	01/30/2001	
R26		6,20 p,993	Cote et al.	03/13/2001	
Examiner Signature	٦,	Kelew A	nler Date	sidered 12/8/0	os

U.C. DATENT DOCUMENT

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ¹Med Colument by the supportinet symbols is indicated on the document under WIPO Standard ST. is (if possible. ² Applicant is to place a check mark her if Baglish

Burden Hoat Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND PEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0031**
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete If Known 10/622,833 Application Number July 21, 2003 Filing Date Richard A. SCHUMACHER et al First Named Inventor Unassigned 1626 Group Art Unit Examiner Name Unassigned MEMORY-28

(use as many sheets as necessary) of 5

Substitute for form 1449A/PTO

U.S. PATENT DOCUMENTS U.S. Patent Document Examine Date of Publication of Pages, Columns, Lines, Where Cite Name of Patentee or Kind Code² r Initials Applicant Cited Document Relevant Passages or Relevant of Cited Document MM-DD-YYYY Figures Appear 03/20/2001 6,204,275 Friesen et al. 06/12/2001 6.245.774 Warrellow et al. 6,297,264 Head et al. 10/02/2001 5,880,135 3/9/1999 6,262,040 7/17/2001 3/21/2000

Attorney Docket Number

FORE	IGN PATENT DOCUM	MENIS		
reign Patent Document	Maria of Constant	Date of Data stient	Pages, Columns, Lines,	Г

Cite No.1	Office ³ FR EP EP WIPO WIPO	Number ⁴ 2729142 1116711 0994100 00/71129	Kind Code ³ (if known) A1 A2	or Applicant of Cited Document Nadler et al. Chassot et al	of Cited Document MM-DD-YYYY 07/12/1996 07/18/2001	Where Relevant Passages or Relevant Figures Appear	T ₆
5	EP EP WIPO	1116711 0994100	A2	Chassot et al			
2	EP WIPO	0994100			07/19/2001		
2	WIPO		Al		07/18/2001		
7		00/71129		Shinji et al.	04/19/2000		
7	WIPO		Al	Hunt et al	11/30/2000		
		94/27971	Al	Nadler et al.	12/08/1994		
	WIPO	93/25517			12/23/1993		
5	WIPO	94/14742			07/07/1994		
6	WIPO	98/58901			12/30/1998		
(JP	11-189577			07/13/1999		
6	WIPO	96/23754			08/08/1996		
3	WIPO	99/33806		John et al.	07/1999		
4	WIPO	96/36620		Giulio et al	11/1996		
	WO	-00/64874			11/2/00		
*	WO	01/70738	1		9/27/01		
4	wo	94/02465			2/3/94		
4	wo	95/01338			1/12/95		
4	JP	2001 11047			1/16/2001		
4	wo	02 059110		PCT	8/1/2002		
25	wo	97 00868		PCT	1/9/1997		1
2	wo	98 09961		PCT	3/12/1998		2
3	wo	97 49702		PCT	12/31/1997		3
	WO	00 69841		PCT	11/23/2000		
	8	WO WO WO	WO 02 059110 WO 97 00868 WO 98 09961 WO 97 49702 WO 00 69841	WO 02 059110 WO 97 00868 6 WO 98 09961 6 WO 97 49702 0 WO 00 69841	WO 02 059110 PCT WO 97 00868 PCT WO 98 09961 PCT WO 97 49702 PCT	WO 02:059110 PCT 8/1/2002 WO 97:00868 PCT 19/1997 6 WO 98:05961 PCT 3/12/1998 6 WO 97:9702 PCT 12/21/1997 0 WO 00:9841 PCT 11/23/2000	WO 02.059110 PCT 81/10/002 WO 97.00868 PCT 16/19/97 WO 98.00961 PCT 37/12/98 WO 97.49762 PCT 37/12/99 WO 06.69841 PCT 11/23/2000

*EXAMINER: Initial if reference consider with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

*Unique citation designation number. * See attached Kinds of U.S. Patent Documents. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.)) * For Japanese patent documents, the indication of the year of the rigin aft the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under MPOS candred ST. in for install.* Of install. * Application of the content and on the attached.*

Burden Nour Statement. This form is estimated to take 2.0 hours to complete. Time will very deprinting upon the needs of tak individual case. Any comments on the annours of sime you see required to complete take from blood by seet to the Chaif Information Officer, U.S. Pener and Trademark Officer, Washington, D. 2021. DO NOT SEND PIES OR COMPLETED FORMS TO TITOR ADMISSISS. SIND 10 - Assistance. Commissioner for Pener Assistance Commissioner for

alreally considered on 1/16 ps IDS no

Under the Paperwork Reduction Act of 1995, no persons are requ

Substitute for form 1449A/PTO Complete If Known 10/622,833 Application Number INFORMATION DISCLOSURE Filing Date July 21, 2003 STATEMENT BY APPLICANT First Named Inventor

MAR 1 2 (use as many sheets as necessary) 3 of SATOLA PRADER

Richard A. SCHUMACHER et al Group Art Unit Unassigned Examiner Name Unassigned Attorney Docket Number MEMORY-28

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(5), volume-issue number(s), publisher, eity and/or country where published.	τ;
R		HEILMAN et al, "Synthesis and Antiinflammatory Evaluation of Substituted Isophthalonitriles, Trimesonitriles, Benzonitriles, and Terephthalonitriles", Journal of Medicinal Chemistry, 1978, Vol. 21, No. 9, pp. 906-913, XP-002226236	
RO		WATANABE et al, "Structure-Activity Relationship and Rational Design of 3,4-Dephostatin Derivatives as Protein Tyrosine Phosphatase Inhibitors", Pergamon Tetrahedron, 2000, Vol. 56, pp. 741-752	
A		INOUE et al, "Steric Tuning in Chiral Ligand Mediated Enanticselective Alkylation of Imines", Tetrahedron: Asymmetry, 1993, Vol. 4, No. 7, pp. 1603-1606, XP002226237	
Ro		THOMAS C. MCKENZIE et al., "The Gomberg-Bachmann Reaction of Purines", J. Heterocyclic Chem., May-Jun 1987, pp. 859-861, Vol. 24	
RA		VASU NAIR et al., "Novel, Stable Congeners of Antiretroviral Compound 2', 3'- Dideoxyadenosine," J. Am. Chem. Soc., 1989, pp. 8502-8504, Vol. 111	
Rb		VASU NAIR et al., "Synthesis Of Congeners Of Adenosine Resistant To Deamination By Adenosine Deaminase," <u>J. Chem. Soc Comm.</u> , 1989, pp. 878-879	
Rt		JAMES L. KELLEY et al., "Synthesis and Structure. Activity Relationships of 2-Substituted-6- (dimethylamino)- 9-(4-methylbenzyl)-9H-purines with Antirhinovirus Activity," J. Med. Chem., 1989, pp. 218-224, Vol. 32	
Rb		JAMES E. KELLEY et al., "Antirhinovirus structure-activity relationships of 6-substituted-9-(4-methylbenzyl)-2-trifluoromethyl-9H-purines," <u>Eur. J. Med. Chem.</u> , 1990, pp. 131-135, Vol. 25	

Examiner Signature Date Considered EXAMINER: Initial if reference considered whather or not citation is in confo considered. Include copy of this form with next communication to applicant nce with MPEP 609. Draw line through citation if not in conformance and not

^{&#}x27;Using or quiton designation number.' See stander Kinds of U.S. Parent Doesment. *Bates Office hat based the document by the two-friet code (VIPO Standard STS). Test allowed and decements. *Bates of the standard for the standard of the standard for the standard

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to emplete this form should be sent to the Cele formation Officer, U.S. Pattert and Trademark Office, Washington, DC 20231.

DO NOT SEND PEES DR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Plents, Washington, DC 20231.

Substitute for form 1449A/PTO

rs

RB

10/622 833

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Application Number

INFO	RMAT	TON DIS	CLOSURE	Filing Date	July 21, 2003			
STAT	EME	NT BY A	PPLICANT	First Named Inventor	Richard A. SCHUMACHER	et al		
				Group Art Unit	Unassigned 1626			
· (use as m	any sheets as	necessary)	Examiner Name	Unassigned			
95get	4	of	5	Attorney Docket Number	MEMORY-28			
m w						_		
UPP		от	HER PRIOR ART NO	N PATENT LITERATURE DO	CUMENTS			
Examiner Initials •	Cite No.1		ine, journal, serial, sympo:		(when appropriate), title of the item volume-issue number(s), publisher,	T²		
R		ROGER J		gh-Throughput Assay For Cyclic Biochemistry, 1994, pp.154-158,	Nucleotide Phosphodiesterases," Vol. 215			
Ro			DONALD V. DANIELS et al., "A Semiautomated Method for the Assay of Cyclic Adenosine 5'- Monophosphate Phosphodiesterase," <u>Analytical Biochemistry</u> , 1996, pp. 367-369, Vol. 236					
Rh		JEAL		NON et al., "9-Benzyladenines: bitors," <u>J. Med. Chem.</u> , 1997, pp.				
no		JAMES L		ylamino)-9-alkylpurines. A New Med. Chem., 1997, pp. 3207-3216	Class of Potential Antipsychotic i, Vol. 40			
jls.		HIROY		Selective Inhibitors of Cyclic Al- Purines", J. Med. Chem., 1997, pp				
Rb		J.E. SO		or Pharmacologically Distinct Con ', Cell Signal, 1997, pp. 227-236				

MARY ELIZABETH BACH et al., "Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway", Proc. Natl. Acad. Sci. USA, April 1999, pp. 5280-5285, Vol. 96
ELISABETH BOICHOT et al., "Anti-Inflammatory Activities of a New Series of Selective

Phosphodiesterase 4 Inhibitors Derived from 9- Benzyladenine," The Journal Of Pharmacology And Experimental Therapeutics, 2000, pp. 647-653, Vol 292, No.2 Anil S. GURAM et al., "A Simple Catalytic Method for the conversion of Aryl Bromides to Arylamines," Angew. Chem. Int, Ed. Engl., 1995, Vol. 34, No. 12, pp. 1348-1350. Michael S. DRIVER et al., "A Second-Generation Catalyst for the Aryl Halide Amination: Mixed Secondary Amines from Aryl Halides and Primary Amines Catalyzed by (DPPF)PdCls," J. Am. Chem. Soc., 1996. Vol. 118, pp. 7217-7218. Takashi EGAWA et al., "Rolipram and its Optical Isomers, Phosphodiesterase 4 Inhibitors, Attenuated the Scopolamine-Induced Impairments of Learning and Memory in Rats." J. Pharmacol., Vol. 75, 275-281(1997). Peng WANG et al., "Expression, Purification, and Characterization of Human cAMP-Specific

Phosphodiesterase (PDE4) Subtypes A, B, C, and D, Biochem. And Biophys. Research Comm., Vol. 234, 320-324 (1997).

	In. I
Signature Lebens Andles	Date Considered /2/8/0

EXAMINER: Initial if reference considered, whether or not eitation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of big form with next communication to applicant.

Unique citation designation number, ² Applicant is to place a check must here if English language, Translation is stratched. Buttern I-Im Strain is estimated to late 2-0 hours to complete. Time will vary depending upon the needed of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Transmark Officer, Washington, Do (2021), LON ON'S BEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant of the Chief Information Officer, U.S. Patent and Transmark Officer, Vashington, Do (2021), LON ON'S BEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant of the Chief Information Officer, U.S. Patent and Transmark Officer, Vashington, Do. (2021), LON ON'S BEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant of the Chief Information Officer, U.S. Patent and Transmark Officer, Vashington, Do. (2021), LON ON'S BEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant of the Chief Information Officer, U.S. Patent and Transmark Officer, Vashington, Do. (2021), LON ON'S BEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant of the Chief Information Officer, U.S. Patent and Transmark Off Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE-Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	form 1449A/PT	0			Complete If Known
				Application Number	10/622,833
INFOR	MATION	DISCL	OSURE	Filing Date	July 21, 2003
STATE	MENTE	Y APP	LICANT	First Named Inventor	Richard A. SCHUMACHER et al
٠				Group Art Unit	Unassigned 1626
· 벨 (u	se as many sh	eets as nec	essary)	Examiner Name	Unassigned
Sheet	5	of	5	Attorney Docket Number	MEMORY-28

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т,
Ro		JAMES E. KELLEY et al., "Antirhinovirus especture activity relationships of 6-substituted-9-(4- methylbenzyl)-2-trifluoromethyl-9H-purines," Eur. J. Med. Chem., 1990, pp. 131-135, Vol. 25	-
B		Domine M. T. CHAN et al., "New N- abd O-Arylations with Phenylboronic Acids and Cupric Acetate," Tetrahedron Letters, Vol. 39, 2933-2936 (1998).	
R		Mark BARAD et al., "Rolipram, a Type IV-Specific Phosphodiesterase Inhibitor Facillitates the Establishment of Long-lasting Long-term Potentiation and Improves Memory," Proc. Natl. Acad. Sci., Vol. 95, pp. 15020-15025 (Docember 1998).	
RL		Miles D. HOUSLAY et al., "The Multienzyme PDEA Cyclic Adenosine Monophosphate-Specific Phosphodieterarse Family, Intacellulate Tageting, Regulation, and Selective Inhibition by Compounds Exerting Anti-inflammatory and Antidepressant Actions," <u>Advances in Pharmacology</u> , Vol. 44, pp. 225-342, 1998.	
R		John HARTWIG et al., "Room-Temperature Palladium-Catalyzed Amination of Aryl Bromides and Chlorides and Extended Scope of Aromatic C-N Bond Formation with a Commercial Ligand," J. Org. Chem., 1999, Vol. 64, pp. 5375-5580.	
0		Han-Ting ZHANG et al., "Inhibition of Cyclic AMP Phosphodiesterase (PDE4) Reverses Memory Deficits Associated with NDMA Receptor Antagonism," Neuropsychopharmacology, 2000, Vol. 23, pp. 198-204.	
160		Han-Ting ZHANG et al., "Effects of Rolipram on Scopolamine-induced Impairment of Working and Reference Memory in the Radial-arm Maze tests in Rats," Psychopharmacology (Berl) 2000 June; 150(3):pp. 311-6.	
Ŗŧ		T.W. Greene et al., <u>Protective Groups in Organic Synthesis</u> , 3 rd Edition, Chapter 3, "Protection for Phenols and Catechols," pp. 246-292, John Wiley & Sons, 1999	
/RA/		International Search Report from PCT Application No. PCT/US02/01508, dated January 16, 2003	

Signature	Kelen	Ander	Considered	12/8/06	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in					
conformance and not considered. Include copy of this form with next communication to applicant.					
		\sim			

Burden Mour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual ease. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patient and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.